Elranatamab, now Elrexfio, approved for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has granted conditional approval to Pfizer‘s elranatamab — an antibody therapy to be marketed under the brand name Elrexfio — for adults with difficult-to-treat multiple myeloma. Eligible patients will have received at least four prior lines of therapy, including a…